LV12271B - Combination pediatric vaccine with enhanced immunogenicity of each vaccine component - Google Patents

Combination pediatric vaccine with enhanced immunogenicity of each vaccine component Download PDF

Info

Publication number
LV12271B
LV12271B LVP-99-29A LV990029A LV12271B LV 12271 B LV12271 B LV 12271B LV 990029 A LV990029 A LV 990029A LV 12271 B LV12271 B LV 12271B
Authority
LV
Latvia
Prior art keywords
vaccine
antigen
diphtheria
tetanus
pertussis
Prior art date
Application number
LVP-99-29A
Other languages
English (en)
Latvian (lv)
Other versions
LV12271A (lv
Inventor
Peter R. Paradiso
Deborah A. Hogerman
Dace Viceps Madore
Jill G. Hackell
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of LV12271A publication Critical patent/LV12271A/xx
Publication of LV12271B publication Critical patent/LV12271B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
LVP-99-29A 1992-10-27 1999-02-22 Combination pediatric vaccine with enhanced immunogenicity of each vaccine component LV12271B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96699592A 1992-10-27 1992-10-27

Publications (2)

Publication Number Publication Date
LV12271A LV12271A (lv) 1999-05-20
LV12271B true LV12271B (en) 1999-07-20

Family

ID=25512167

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-29A LV12271B (en) 1992-10-27 1999-02-22 Combination pediatric vaccine with enhanced immunogenicity of each vaccine component

Country Status (22)

Country Link
EP (1) EP0594950B1 (cs)
JP (1) JPH07300427A (cs)
KR (1) KR100289224B1 (cs)
AT (1) ATE176157T1 (cs)
AU (1) AU669570B2 (cs)
CA (1) CA2109159A1 (cs)
CZ (1) CZ283587B6 (cs)
DE (2) DE69323264T4 (cs)
DK (1) DK0594950T3 (cs)
ES (1) ES2126616T3 (cs)
FI (1) FI934725A7 (cs)
GR (1) GR3029884T3 (cs)
HU (1) HU215149B (cs)
IL (1) IL107387A (cs)
LV (1) LV12271B (cs)
NO (1) NO308588B1 (cs)
NZ (1) NZ250029A (cs)
PL (1) PL174130B1 (cs)
RU (1) RU2121365C1 (cs)
SG (1) SG47725A1 (cs)
TW (1) TW256774B (cs)
UA (1) UA27754C2 (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024216A1 (en) * 1994-03-07 1995-09-14 Auckland Uniservices Limited Prevention of diabetes
CZ390297A3 (cs) * 1995-06-07 1998-05-13 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
BRPI9609414B8 (pt) 1995-06-23 2021-05-25 Smithkline Beecham Biologicals S A combinação de vacina e kit para produzir a mesma.
WO1998000167A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU227613B1 (en) * 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
RU2175557C1 (ru) * 2000-09-04 2001-11-10 Волков Александр Григорьевич Способ предупреждения воспалительных заболеваний верхних дыхательных путей
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
PT1556477T (pt) 2002-11-01 2017-11-14 Glaxosmithkline Biologicals Sa Processo de secagem
RU2231793C1 (ru) * 2003-03-11 2004-06-27 Москаленко Екатерина Петровна Способ оценки иммуногенности коклюшных вакцин
RU2244548C1 (ru) * 2003-07-17 2005-01-20 Оренбургская государственная медицинская академия (ОГМА) Средство, повышающее иммуногенные свойства столбнячного анатоксина
RU2274474C1 (ru) * 2004-10-12 2006-04-20 Государственное образовательное учреждение ВПО Красноярская государственная медицинская академия Министерства здравоохранения РФ Способ вакцинации детей против краснухи на крайнем севере
GB0505996D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
RU2303459C1 (ru) * 2005-12-05 2007-07-27 ГУ научно-исследовательский институт медицинских проблем Севера СО РАМН (РФ) Способ вакцинации детей против краснухи на крайнем севере
RU2299744C1 (ru) * 2006-03-02 2007-05-27 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ сезонной ревакцинации детей против краснухи на крайнем севере

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ188211A (en) * 1977-10-28 1984-09-28 American Cyanamid Co Isolation of polyribosyl ribitol phosphate(prp)from haemophilus influenzae type b;vaccine comprising prp and bordetellapertussis antigens
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen

Also Published As

Publication number Publication date
NO308588B1 (no) 2000-10-02
JPH07300427A (ja) 1995-11-14
ES2126616T3 (es) 1999-04-01
DE69323264T4 (de) 1999-10-14
KR100289224B1 (ko) 2001-05-02
FI934725L (fi) 1994-04-28
PL174130B1 (pl) 1998-06-30
HK1009931A1 (en) 1999-06-11
HUT67239A (en) 1995-03-28
NZ250029A (en) 1994-09-27
HU9303028D0 (en) 1994-01-28
TW256774B (cs) 1995-09-11
EP0594950A1 (en) 1994-05-04
EP0594950B1 (en) 1999-01-27
IL107387A0 (en) 1994-01-25
KR940008698A (ko) 1994-05-16
UA27754C2 (uk) 2000-10-16
CA2109159A1 (en) 1994-04-28
AU5029093A (en) 1994-05-12
NO933856L (no) 1994-04-28
FI934725A0 (fi) 1993-10-26
LV12271A (lv) 1999-05-20
HU215149B (hu) 2000-03-28
AU669570B2 (en) 1996-06-13
NO933856D0 (no) 1993-10-26
RU2121365C1 (ru) 1998-11-10
FI934725A7 (fi) 1994-04-28
ATE176157T1 (de) 1999-02-15
CZ283587B6 (cs) 1998-05-13
GR3029884T3 (en) 1999-07-30
DE69323264T2 (de) 1999-06-02
DK0594950T3 (da) 1999-09-13
CZ227293A3 (en) 1994-05-18
IL107387A (en) 1997-04-15
DE69323264D1 (de) 1999-03-11
SG47725A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
EP0594950B1 (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
JP5637848B2 (ja) 髄膜炎ワクチンの製剤化
JP4871770B2 (ja) 組み合わせ髄膜炎ワクチン
US6329512B1 (en) Immunogenic conjugate molecules
Weinberg et al. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitidis outer membrane protein conjugate vaccine
RU2444374C2 (ru) Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество
Alexander et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®)
JP2010529103A5 (cs)
PT1946772E (pt) Composição de vacina multivalente
AU2010200249A1 (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
SK283565B6 (sk) Multivalentná imunogénna kompozícia a jej použitie
EP2661277A2 (en) A combination heptavalent vaccine
Kennedy et al. Measuring immune response to commonly used vaccinations in adult recipients of allogeneic hematopoietic cell transplantation
Zhao et al. Polysaccharide conjugate vaccine: A kind of vaccine with great development potential
CA2855224A1 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
RU2420315C2 (ru) Комбинированные вакцины с антигеном коклюша цельных клеток
Redhead et al. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity
HK1009931B (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
EP2592137A1 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
Yewale et al. Varicella Vaccines
Vella et al. Haemophilus b conjugate vaccines
Schedule et al. Supplementary Table 1: Trials included in Hib conjugate vaccine review, detailed information
PL174077B1 (pl) Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)
Gotschlich Immune response to the meningococcal group-specific polysaccharides
GB2498112A (en) Preparation of a diphtheria toxoid by incubating toxin concentrate with an amino acid and formaldehyde